Comparative Pharmacology
Head-to-head clinical analysis: STAVUDINE LAMIVUDINE NEVIRAPINE versus STAVUDINE LAMIVUDINE W NEVIRAPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STAVUDINE LAMIVUDINE NEVIRAPINE versus STAVUDINE LAMIVUDINE W NEVIRAPINE.
STAVUDINE; LAMIVUDINE; NEVIRAPINE vs STAVUDINE; LAMIVUDINE W/NEVIRAPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stavudine is a nucleoside analog reverse transcriptase inhibitor (NRTI) that inhibits HIV reverse transcriptase. Lamivudine is an NRTI that inhibits HIV reverse transcriptase. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to HIV reverse transcriptase, causing enzyme inhibition.
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits HIV-1 reverse transcriptase by competing with the natural substrate thymidine triphosphate and by causing DNA chain termination after incorporation. Lamivudine is an NRTI that inhibits HIV-1 reverse transcriptase via similar mechanisms. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to reverse transcriptase and blocks RNA-dependent and DNA-dependent DNA polymerase activities.
One tablet (stavudine 30 mg + lamivudine 150 mg + nevirapine 200 mg) orally twice daily. For patients weighing ≥60 kg, stavudine 40 mg may be used; however, due to toxicity, 30 mg is preferred. Nevirapine requires a 14-day lead-in dose of 200 mg once daily.
One tablet (stavudine 30 mg / lamivudine 150 mg / nevirapine 200 mg) orally twice daily.
None Documented
None Documented
Stavudine: 1.0-1.6 hours (mean ~1.5 h) in adults with normal renal function; prolonged in renal impairment. Lamivudine: 5-7 hours in adults; prolonged in renal impairment. Nevirapine: 25-30 hours (single dose); 40-45 hours with multiple dosing due to autoinduction.
Stavudine: 0.9–1.6 h (normal renal function), prolonged in renal impairment; lamivudine: 5–7 h (adults), 2–4 h (children); nevirapine: 25–30 h (terminal, after multiple doses), allowing once-daily dosing.
Stavudine: Renal (approximately 60% unchanged) and hepatic metabolism. Lamivudine: Renal (approximately 70% unchanged) via glomerular filtration and active tubular secretion. Nevirapine: Hepatic metabolism (CYP3A4, CYP2B6) followed by renal excretion of metabolites (about 80% in urine, 10% in feces).
Stavudine: 50% excreted unchanged in urine via glomerular filtration and active tubular secretion; lamivudine: ~70% excreted unchanged in urine via active secretion; nevirapine: ~80% metabolized by liver, with <5% excreted unchanged in urine (metabolites eliminated renally and fecally).
Category A/B
Category A/B
NRTI
NRTI